CME Group director receives 645-share equity grant

Suskind Dennis reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Suskind Dennis reported acquisition or exercise transactions in this Form 4 filing.

CME Group Inc. director Dennis Suskind received a grant of 645 shares of Class A Common Stock on June 25, 2026 as equity compensation. The shares were valued at $225.00 per share for reporting purposes and were issued under the CME Group Director Stock Plan.

These shares are fully vested and not subject to any vesting conditions, meaning Suskind has immediate rights to them. Following this grant, he directly holds a total of 3,344 shares of CME Group Class A Common Stock. This is a routine, compensation-related award rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 645 shares

Grant/Award 1 txn

Insider Suskind Dennis

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock Class A	645	$225.00	$145K

Holdings After Transaction: Common Stock Class A — 3,344 shares (Direct)

Footnotes (1)

1. F1. Represents a grant of fully vested shares of Class A Common Stock issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. These shares are not subject to any vesting conditions.

Key Figures

Equity grant size: 645 shares Reported grant price: $225.00 per share Post-transaction holdings: 3,344 shares

3 metrics

Equity grant size 645 shares Class A Common Stock grant to director Dennis Suskind on June 25, 2026

Reported grant price $225.00 per share Reference price used for the 645-share equity award

Post-transaction holdings 3,344 shares Dennis Suskind’s direct Class A Common Stock holdings after the grant

Key Terms

annual equity compensation program, CME Group Director Stock Plan, fully vested shares, Class A Common Stock

4 terms

annual equity compensation program financial

"issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors"

CME Group Director Stock Plan financial

"for non-employee directors under the CME Group Director Stock Plan"

fully vested shares financial

"Represents a grant of fully vested shares of Class A Common Stock"

Class A Common Stock financial

"Represents a grant of fully vested shares of Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

What insider transaction did CME (CME) report for Dennis Suskind?

CME Group reported that director Dennis Suskind received 645 shares of Class A Common Stock as an equity grant. The award is part of the company’s annual compensation program for non-employee directors under the CME Group Director Stock Plan.

Was Dennis Suskind’s CME (CME) share grant an open-market purchase?

No, Dennis Suskind’s 645-share transaction was a compensation grant, not an open-market purchase. The filing describes it as a grant or award of fully vested Class A Common Stock under CME Group’s Director Stock Plan for non-employee directors.

What is the reported value of Dennis Suskind’s CME (CME) equity grant?

The 645 granted shares were reported at $225.00 per share for Form 4 purposes. This implies a disclosed grant value based on that reference price, reflecting the compensation value of the fully vested Class A Common Stock award he received.

How many CME (CME) shares does Dennis Suskind hold after this grant?

After receiving the 645-share grant, Dennis Suskind directly holds 3,344 shares of CME Group Class A Common Stock. This total reflects his direct ownership position following the compensation award reported in the Form 4 insider trading filing.

Are Dennis Suskind’s new CME (CME) shares subject to vesting conditions?

No, the filing states the 645 shares are fully vested and not subject to any vesting conditions. They were granted under the CME Group Director Stock Plan as part of the annual equity compensation program for non-employee directors.

What plan governs Dennis Suskind’s CME (CME) share award?

The award was made under the CME Group Director Stock Plan. The filing explains it is part of CME Group’s annual equity compensation program for non-employee directors and consists of fully vested Class A Common Stock with no vesting restrictions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Suskind Dennis

(Last) (First) (Middle)

20 S. WACKER DRIVE

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	06/25/2026		A(1)		645	A	$225	3,344	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of fully vested shares of Class A Common Stock issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. These shares are not subject to any vesting conditions.

Remarks:

	/s/ Elizabeth Hensen, as Attorney-in-Fact for Dennis A. Suskind	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)